Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase

Heudobler, Daniel and Lueke, Florian and Hahn, Joachim and Grube, Matthias and Schlosser, Pavla and Kremers, Stephan and Suedhoff, Thomas and Westermann, Joerg and Huetter-Kroenke, Marie Luise and Schlenk, Richard F. and Weber, Daniela and Paschka, Peter and Zeman, Florian and Doehner, Hartmut and Herr, Wolfgang and Reichle, Albrecht and Thomas, Simone (2024) Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase. HAEMATOLOGICA, 109 (4). pp. 1274-1278. ISSN 0390-6078, 1592-8721

Full text not available from this repository. (Request a copy)
Item Type: Article
Uncontrolled Keywords: DECITABINE
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Klinische Studien
Depositing User: Dr. Gernot Deinzer
Date Deposited: 22 Oct 2025 06:36
Last Modified: 22 Oct 2025 06:36
URI: https://pred.uni-regensburg.de/id/eprint/64057

Actions (login required)

View Item View Item